Exagen (XGN) EBIAT (2018 - 2025)
Exagen (XGN) has disclosed EBIAT for 8 consecutive years, with -$4.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 24.25% year-over-year to -$4.7 million, compared with a TTM value of -$20.0 million through Dec 2025, down 31.99%, and an annual FY2025 reading of -$20.0 million, down 31.99% over the prior year.
- EBIAT was -$4.7 million for Q4 2025 at Exagen, up from -$7.1 million in the prior quarter.
- Across five years, EBIAT topped out at -$3.0 million in Q2 2024 and bottomed at -$14.7 million in Q2 2022.
- Average EBIAT over 5 years is -$6.6 million, with a median of -$5.9 million recorded in 2021.
- The sharpest move saw EBIAT tumbled 128.78% in 2022, then skyrocketed 65.82% in 2023.
- Year by year, EBIAT stood at -$7.1 million in 2021, then plummeted by 103.52% to -$14.4 million in 2022, then soared by 61.17% to -$5.6 million in 2023, then soared by 32.51% to -$3.8 million in 2024, then fell by 24.25% to -$4.7 million in 2025.
- Business Quant data shows EBIAT for XGN at -$4.7 million in Q4 2025, -$7.1 million in Q3 2025, and -$4.4 million in Q2 2025.